Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 30, 2011. The report focuses on a specific legal development regarding the company's marketing rights for the product LOVAZA in the United States and Puerto Rico.
Key Financial Metrics
The filing provides historical sales data for LOVAZA but does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
- LOVAZA 2010 Turnover: £530 million ($822 million).
- Geographic Scope: All reported LOVAZA sales were generated in the US and Puerto Rico.
Material Changes and Litigation Status
The primary material change reported is a settlement agreement regarding patent litigation for LOVAZA.
- Settlement with Apotex: Pronova BioPharma Norge AS (patent owner) and GSK (marketing rights holder) reached an agreement with Apotex Corp. and Apotex Inc. to settle US patent litigation.
- Market Entry: The settlement grants Apotex a license to enter the US market with a generic version of LOVAZA in the first quarter of 2015, or earlier depending on certain circumstances.
- Ongoing Litigation: Pronova BioPharma remains involved in lawsuits with Teva Pharmaceuticals USA, Inc., and Par Pharmaceutical, Inc. regarding LOVAZA patents.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future earnings projections. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties.
- Risk Reference: Investors are directed to the "Risk Factors" section in the "Business Review" of the company's Annual Report on Form 20-F for 2010 for a detailed description of factors affecting operations.
Key Facts for Investor Verification
- Verify the specific terms of the settlement with Apotex, as the filing states other terms are confidential.
- Monitor the status of ongoing litigation with Teva Pharmaceuticals and Par Pharmaceutical, which could impact the timeline for generic competition.
- Assess the potential impact of the 2015 generic entry date on future LOVAZA revenue streams, given the product's £530 million turnover in 2010.
- Review the 2010 Form 20-F for comprehensive risk factors not detailed in this specific 6-K filing.